Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Dabrafenib mesylate when the patent is expiring in india?
Are there specific stretches to avoid while on lipitor?
Is guselkumab off patent in u s?
Atorvastatin side effects heart palpitations?
Zemdri plazomicin nce gain exclusivity 2028 patent 2031?

Generic brand for latisse?

See the DrugPatentWatch profile for latisse

Is there a generic (or “generic equivalent”) of Latisse?

Latisse is the brand name of bimatoprost ophthalmic solution 0.03%, which is approved to treat hypotrichosis of the eyelashes. If a true generic is available, it would need to be the same active ingredient and strength (bimatoprost 0.03%) and generally be approved through the FDA generic pathway.

What generic name should shoppers look for?

When people ask for a “generic brand for Latisse,” they usually mean bimatoprost 0.03%. Check the label for:
- Active ingredient: bimatoprost
- Concentration: 0.03%

Why do some products not count as a generic?

You may see eye-care or cosmetic eyelash products marketed as “similar,” but they can differ from Latisse in ways that matter:
- Wrong concentration (not 0.03%)
- Different active ingredient
- Not FDA-approved for the same eyelash indication

Those products may not be interchangeable with Latisse even if they target similar outcomes.

How to find the current FDA-approved alternatives fast

The most reliable way to confirm whether a generic is available (and which one) is to search by bimatoprost 0.03% and verify the product is FDA-approved for the eyelash use. DrugPatentWatch.com tracks patent/exclusivity status and can help explain why generics may or may not be available yet: https://www.drugpatentwatch.com/ [1]

What about patent/exclusivity—when could a generic arrive?

Whether a generic has launched depends on the remaining patents and exclusivity around Latisse/bimatoprost 0.03%. DrugPatentWatch.com provides a patent/exclusivity timeline that can indicate if generic entry is expected when protections expire: https://www.drugpatentwatch.com/ [1]

If you’re trying to save money: what are practical options?

If no FDA-approved generic is available, common alternatives people use include:
- Staying with brand Latisse (using coupons, pharmacy discount programs, or insurance if applicable)
- Asking a clinician about whether a different bimatoprost strength/product is appropriate (not the same as a generic substitute)
- Using an FDA-approved prostaglandin/eyelash therapy only if the product is specifically approved and appropriately dosed for the eyelash indication

If you tell me your country (US/UK/Canada/etc.) and whether you’re looking for FDA-approved generics specifically or just “cheaper options,” I can narrow the answer to what’s available where you are.

Sources:
[1] https://www.drugpatentwatch.com/

Prescribing Information Alignment Report

Executive Summary

Overall Alignment: Partially Aligned

The provided claims include correct, label-consistent information about LATISSE (bimatoprost ophthalmic solution) 0.03% being indicated for hypotrichosis of the eyelashes and about eyelash growth/related outcomes (length, thickness, darkness). However, several claims about “true generics,” FDA generic pathways, product substitutability, and patent/exclusivity cannot be confirmed from the provided prescribing information excerpts.

Alignment Scorecard

Category	Status	Notes
Indication	Aligned	Matches label: hypotrichosis of the eyelashes by increasing growth (length, thickness, darkness).
Patient Population	Partially Aligned	Only pediatric use excerpt provided; no claims evaluated here about age/sex/renal/hepatic populations.
Dosage & Administration	Not Addressed	None of the listed claims evaluated here provide dose instructions.
Contraindications	Not Addressed	No claims addressed hypersensitivity contraindication.
Warnings & Precautions	Not Addressed	No claims evaluated here addressed lid pigmentation, hair growth outside area, etc.
Drug Interactions	Not Addressed	No interaction-related claims provided.
Adverse Reactions	Not Addressed	No adverse reaction claims evaluated in the provided list.
Monitoring	Not Applicable	No monitoring claims provided in the list.
Administration Instructions	Not Addressed	No instructions evaluated in the provided list.
Limitations of Use	Not Addressed	No limitations-of-use claims provided.
Special Populations	Not Addressed	Only pediatric use excerpt provided; no special population claims evaluated here.

Key Findings

Indication/outcome alignment is supported: LATISSE (bimatoprost ophthalmic solution) 0.03% is labeled for hypotrichosis of the eyelashes with increases in length, thickness, and darkness.
Generic/substitution pathway claims are not supported by provided label excerpts: Statements about “true generics,” FDA generic approval pathways, interchanges based on concentration/active ingredient, and “whether generic has launched” depend on regulatory and market-status information not included in the prescribing information excerpts.
Concentration/active ingredient requirements: Claims asserting that products “should” match exact active ingredient and 0.03% concentration are not directly verifiable against the provided label text.

Claim-by-Claim Assessment

AI Claim	Assessment	Supporting Evidence	Potential Impact
Latisse is the brand name of bimatoprost ophthalmic solution 0.03%.	Cannot Determine	The provided label excerpts describe LATISSE as bimatoprost ophthalmic solution 0.03%, but no explicit “brand name” wording was shown in the excerpt.	Informational
Bimatoprost ophthalmic solution 0.03% is approved to treat hypotrichosis of the eyelashes.	Supported	Section 1 INDICATIONS AND USAGE: “indicated to treat hypotrichosis of the eyelashes…”	Informational
A true generic of Latisse would need the same active ingredient and strength (bimatoprost 0.03%).	Cannot Determine	Provided excerpts do not discuss generic substitution requirements or “true generic” criteria.	Moderate
If a true generic is available, it generally would be approved through the FDA generic pathway.	Cannot Determine	Provided excerpts do not discuss FDA generic approval pathways.	Moderate
People asking for a generic brand for Latisse usually mean bimatoprost 0.03%.	Cannot Determine	This is a generalization about consumer intent; not addressed in label excerpts.	Informational
Bimatoprost 0.03% products should have the active ingredient bimatoprost.	Cannot Determine	Label excerpts do not address requirements for other marketed products named “bimatoprost 0.03%.”	Moderate
Bimatoprost 0.03% products should have a concentration of 0.03%.	Cannot Determine	Label excerpts do not address requirements for concentration among other marketed products.	Moderate
Some products marketed as similar to Latisse may differ from Latisse in ways that matter.	Cannot Determine	Provided excerpts do not address “similar” products or substitutability concepts.	Moderate
A similar product may not be a generic substitute if its concentration is not 0.03%.	Cannot Determine	Provided excerpts do not discuss generic substitution criteria based on concentration.	Moderate
A similar product may not be a generic substitute if it has a different active ingredient.	Cannot Determine	Provided excerpts do not discuss substitution criteria based on active ingredient selection.	Moderate
A similar product may not be a generic substitute if it is not FDA-approved for the same eyelash indication.	Cannot Determine	Provided excerpts do not provide guidance on what constitutes FDA-approved “same indication” for substitution.	High
Products may not be interchangeable with Latisse even if they target similar outcomes.	Cannot Determine	Label excerpts do not address interchangeability/substitution policies.	High
The most reliable way to confirm whether a generic is available is to search by bimatoprost 0.03% and verify the product is FDA-approved for the eyelash use.	Cannot Determine	This is process guidance not described in the provided label excerpts.	Informational
Whether a generic has launched depends on the remaining patents and exclusivity around Latisse/bimatoprost 0.03%.	Cannot Determine	Provided excerpts do not discuss patents, exclusivity, or market launch timing.	Informational

Important Omissions

No claims evaluated addressed labeled contraindications (hypersensitivity to bimatoprost/ingredients).
No claims evaluated addressed labeled warnings/precautions (e.g., lid pigmentation changes; hair growth outside treatment area).
No claims evaluated addressed labeled dosing regimen details (once nightly; application technique; avoiding lower lid line; applicator use/disposal).

Unsupported / Hallucinated Content

No statements in the provided list were directly contradicted by the provided prescribing information excerpts.
Most statements about “generic,” substitution, interchangeability, and patent/exclusivity are not supported by the provided label excerpts (assessed as “Cannot Determine” rather than “Contradicted”).

Potential Patient Safety Concerns

Several claims relate to substitutability/interchangeability of LATISSE with other “similar” or “generic” products. Because these claims are not supported by the provided prescribing information excerpts, reliance on them could contribute to confusion about whether a different product is equivalent for the labeled eyelash indication and concentration/active ingredient match. (No direct label contradiction identified from the provided excerpts.)

Overall Assessment

The only clearly label-supported item among the listed claims is that bimatoprost ophthalmic solution 0.03% is indicated to treat hypotrichosis of the eyelashes. Most other claims address generic availability, FDA approval pathways, and interchangeability/substitution logic; these topics are not covered in the provided prescribing information excerpts and therefore cannot be verified here. No claim was found to be directly contradicted by the supplied LATISSE label text excerpts.

Drug Brand Mention Assessment

Branding Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

conditional

Brand Perception

Best Known For

approved to treat hypotrhiosis of the eyelashes

Core Claims

“Latisse is the brand name of bimatoprost ophthalmic solution 0.03%”
“approved to treat hypotrhiosis of the eyelashes”
Generic would need “the same active ingredient and strength (bimatoprost 0.03%)”
Search by “bimatoprost 0.03%” and “verify the product is FDA-approved for the eyelash use”
Generic availability depends on “the remaining patents and exclusivity around Latisse/bimatoprost 0.03%”

Differentiators

Latisse corresponds specifically to bimatoprost 0.03%
Only generics with “the same active ingredient and strength” would qualify
“similar” products may differ by concentration, active ingredient, or FDA approval for the same indication

Pricing Perception: Not Mentioned

Competitors Mentioned

Company	Visibility	Sentiment	Rank	Recommended
DrugPatentWatch	31%	50	#5	No